Kidney cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Merck Sharp & Dohme LLC· Source

• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

  NCT00050752· National Cancer Institute (NCI)· Source

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Hoffmann-La Roche· Source

• A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  NCT05536141· Arcus Biosciences, Inc.· Source

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Arcus Biosciences, Inc.· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

  NCT05891171· Arcus Biosciences, Inc.· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

  NCT00033137· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 4
• Gene Expression Profiling 7
• Mass Spectrometry 2
• Flow Cytometry 10
• Immunohistochemistry 8
• Xenograft Model Antitumor Assays 28
• Positron-Emission Tomography 1
• Cohort Studies 13
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.